Johan Heylen is a seasoned general management professional with more than 20 years of experience in pharma/biotech. He has experience in a wide range of therapeutic fields and regions, having worked and lived in Europe, Latin-America, Asia and in the USA.
As Chief Commercial Officer, Johan assumes responsibility for all commercial activities, business development and late stage project management at Ablynx, one of the world’s leading next generation antibody companies. In view of the commercialization of the first Nanobody-based therapeutic, the orphan drug caplacizumab, Johan defined the global business plan and is currently building the headquarter and affiliates’ structure, including sales, marketing, market access, medical, supply, regulatory, and G&A (HR, IT, legal, finance).
Previously, at GSK, Johan took an innovative cancer immunotherapy from PoC to end of Phase III, defined the global launch plan and business model and set up the organizational structure, people and processes to support strategy and implementation. Preceding, Johan orchestrated the global highly successful launch of 3 pediatric vaccines with overall sales >€1.5 billion.
Johan holds degrees in pharmacy, economics and management. In addition to his duties as CCO of Ablynx, he is lecturer in marketing at the Université Libre de Bruxelles and Director and Member of the Board of FlandersBio.